Neurological disorder drug discovery from gene expression with tensor decomposition

Y-h. Taguchi[†] and Turki Turki^{*}

[†]Department of Physics, Chuo University, Tokyo 112-8551, Japan

^{*}King Abdulaziz University, Department of Computer Science,
Jeddah 21589, Saudi Arabia

October 3, 2019

Abstract

Background: Identifying effective candidate drug compounds in patients with neurological disorders based on gene expression data is of great importance to the neurology field. By identifying effective candidate drugs to a given neurological disorder, neurologists would (1) reduce the time searching for effective treatments; and (2) gain additional useful information that leads to a better treatment outcome. Although there are many strategies to screen drug candidate in pre-clinical stage, it is not easy to check if candidate drug compounds can be also effective to human.

Objective: We tried to propose a strategy to screen genes whose expression is altered in model animal experiments to be compared with gene expressed differentially with drug treatment to human cell lines.

Methods: Recently proposed tensor decomposition (TD) based unsupervised feature extraction (FE) is applied to single cell (sc) RNA-seq experiments of Alzheimer’s disease model animal mouse brain.

Results: Four hundreds and one genes are screened as those differentially expressed during $A\beta$ accumulation as age progresses. These genes are significantly overlapped with those expressed differentially with the known drug treatments for three independent data sets: LINCS, DrugMatrix and GEO.

Conclusion: Our strategy, application of TD based unsupervised FE, is useful one to screen drug candidate compounds using scRNA-seq data set.

keywords: Amyloid, Alzheimer Disease, Gene Expression, Single-Cell Analysis, Drug Discovery, Cell Line

1 Introduction

Drug discovery for neurological disorder has never been successful in spite of massive efforts spent [1]. One possible reason is because we generally do not

28 have suitable model animals for human neurological disorder [2]. Although a
 29 huge number of compounds are screened using model animals, only a few of
 30 them passed the human level screening. In this sense, it is required to screen
 31 candidate compounds using information retrieved from human at the earliest
 32 stage. One possible strategy to do this is the usage of human cell lines; Nev-
 33 ertheless, it is also not easy to perform, since generating cell line from human
 34 neurological disorder patients is not easy. In contrast to the cancer cell lines,
 35 which can be easily generated by immortalizing tumor cells, neuronal cells are
 36 hardly converted to cell lines, since mature neurons do not undergo cell divi-
 37 sion [3]. Therefore, it is difficult to test if candidate drugs work for human
 38 during pre-clinical stages.

39 In order to overcome this difficulty, we proposed an alternative strategy; com-
 40 paring disease gene expression with that of compound treated animals and/or
 41 human cell lines. Generally, compound screening is based upon phenotype; i.e.,
 42 evaluation of compounds efficiency is tested based upon if drug treatment can
 43 produce symptomatic improvement. Nevertheless, since it has been recently
 44 found that various neurological disorders share gene expression [4], focusing on
 45 gene expression profiles might be more reasonable. Following this strategy, we
 46 considered gene expression profiles (single cell RNA-seq) of mouse brain during
 47 amyloid β accumulation. As being aged, some set of gene expression progresses
 48 and significantly overlaps with genes that express differential expression caused
 49 by various compounds treatment. Since top ranked (i.e., with the most overlaps)
 50 detected compounds turn out to be tested previously toward Alzheimer disease
 51 (AD) treatment, lower ranked compounds also might be promising candidate
 52 compounds for AD.

53 Expression levels exhibit variations of scRNA-seq data used in this study
 54 due to contributions specific to genotypes, tissues, ages, sex, plates, wells, and
 55 interactions thereof. Hence, classical unsupervised decomposition methods are
 56 not well-suited to explore the six-way interactions and struggle to extract in-
 57 sights from data, hindering the process of finding effective drug compounds of
 58 a neurological disorder.

59 **Contributions.** Our contributions over existing work are summarized as
 60 follows:

- 61 – Whilst the application of tensor decomposition (TD) to the neurology
 62 domain is not new, previous developments, to the best of our knowledge,
 63 facilitated the neurological drug discovery process are not relevant to mod-
 64 eling the several interactions of scRNA-seq data used in this work. Our
 65 proposed tensor decomposition formalism is new, targeting neurological
 66 drug discovery of AD and constitutes a main contribution of this work.
- 67 – We present findings on an AD with a tensor decomposition formalism
 68 demonstrating the effectiveness of finding compounds for the treatment of
 69 AD.
- 70 – As similar to tensor decomposition techniques, the utilized tensor decom-
 71 position technique works under the unsupervised learning setting which is

more time effective than previous deployments that work under different learning settings, including the supervised learning setting.

– Unlike traditional machine and deep learning approaches that provide solutions to artificial intelligence when applied to plents of neurological disorder problems, our approach blends techniques from linear algebra and statistics to yield a tensor decomposition technique utilizing a statistical linear algebra approach, requiring much less computational resources and time to reach a solution [5–7].

Organization. The rest of the paper is organized as follows. Section 2 introduces the tensor decomposition technique and the provided data to be analyzed. Section 3 presents the experimental results, followed by Section 4 to discuss the results. Section 5 concludes the work and points out future direction.

2 Materials and Methods

2.1 Single cell RNA-seq

Single cell (sc) RNA-seq used in this study was downloaded from gene expression omnibus (GEO) using GEO ID GSE127892. It is composed of two genotypes (APP_NL-F-G and C57Bl/6), two tissues (Cortex and Hippocampus), four ages (3, 6, 12, and 21 weeks), two sex (male and female) and four 96 well plates. For each of combined combinations, four 96 well plates, each of wells includes one cell, were tested. Among those wells tested, wells with insufficient gene expression were discarded. As a result, among 2 (genotype) $\times$ 2 (tissues) $\times$ 4 (ages) $\times$ 2 (sex) $\times$ 4 (plates) $\times$ 96 (wells) = 12288 cells measured, scRNA-seq for only 10801 cells were provided.

2.2 Tensor decomposition based unsupervised feature extraction

We applied recently proposed TD based unsupervised feature extraction (FE) [8–18] to scRNA-seq. A tensor $x_{j_1 j_2 j_3 j_4 j_5 j_6 i} \in \mathbb{R}^{96 \times 2 \times 2 \times 4 \times 2 \times 4 \times 29341}$ that represents gene expression of i th gene of j_1 th cell (well) at j_2 th genotyoe ($j_2 = 1$:APP_NL-F-G and $j_2 = 2$: C57Bl/6), j_3 th tissue ($j_3 = 1$:Cortex and $j_3 = 2$:Hippocampus), j_4 th age ($j_4 = 1$: three weeks, $j_4 = 2$: six weeks, $j_4 = 3$: twelve weeks, and $j_4 = 4$: twenty one weeks), j_5 th sex ($j_5 = 1$:female and $j_5 = 2$:male) and j_6 th plate.

$x_{j_1 j_2 j_3 j_4 j_5 j_6 i}$ is standardized such that $\sum_{i=1}^{29341} x_{j_1 j_2 j_3 j_4 j_5 j_6 i} = 0$ and $\sum_{i=1}^{29341} x_{j_1 j_2 j_3 j_4 j_5 j_6 i}^2 = 29341$. HOSVD [9] was applied to $x_{j_1 j_2 j_3 j_4 j_5 j_6 i}$ such that

$$x_{j_1 j_2 j_3 j_4 j_5 j_6 i} = \sum_{\ell_1=1}^{96} \sum_{\ell_2=1}^2 \sum_{\ell_3=1}^2 \sum_{\ell_4=1}^4 \sum_{\ell_5=1}^2 \sum_{\ell_6=1}^4 \sum_{\ell_7=1}^{29341} G(\ell_1, \ell_2, \ell_3, \ell_4, \ell_5, \ell_6, \ell_7) u_{\ell_1 j_1} u_{\ell_2 j_2} u_{\ell_3 j_3} u_{\ell_4 j_4} u_{\ell_5 j_5} u_{\ell_6 j_6} u_{\ell_7 i} \quad (1)$$

where $G(\ell_1, \ell_2, \ell_3, \ell_4, \ell_5, \ell_6, \ell_7) \in \mathbb{R}^{96 \times 2 \times 2 \times 4 \times 2 \times 4 \times 29341}$ is core tensor, $u_{\ell_1 j_1} \in \mathbb{R}^{96 \times 96}$, $u_{\ell_2 j_2} \in \mathbb{R}^{2 \times 2}$, $u_{\ell_3 j_3} \in \mathbb{R}^{2 \times 2}$, $u_{\ell_4 j_4} \in \mathbb{R}^{4 \times 4}$, $u_{\ell_5 j_5} \in \mathbb{R}^{2 \times 2}$, $u_{\ell_6 j_6} \in \mathbb{R}^{4 \times 4}$ and $u_{\ell_7 i} \in \mathbb{R}^{29341 \times 29341}$ are singular value matrices that are orthogonal matrices. In order to save time to compute, only $1 \leq \ell_1, \ell_7 \leq 10$ were computed (The reason why we employed specifically HOSVD in this research will be discussed in the discussion section, because it is difficult to explain the reason before demonstrating how we make use of TD for data analysis).

After investigation of $u_{\ell_4 j_4}$, $u_{\ell_2 j_2}$ represent monotonic dependence upon age while $\ell_1, \ell_2, \ell_3, \ell_5, \ell_6 = 1$ represent independence of cells, genotype, tissue, sex and plate. Since $G(1, 1, 1, 2, 1, 1, 2)$ has the largest absolute values among $G(1, 1, 1, 2, 1, 1, \ell_7)$, u_{2i} is employed to compute P -values attributed to i th gene as

$$P_i = P_{\chi^2} \left[> \left(\frac{u_{2i}}{\sigma} \right)^2 \right] \quad (2)$$

where $P_{\chi^2}[> x]$ is the cumulative probability of χ^2 distribution when the argument is larger than x and σ is the standard deviation.

P -values are corrected by Benjamini and Hochberg criterion [19] and genes associated with corrected P -values less than 0.01 are selected for downstream analysis.

2.3 Enrichment analysis

Four hundreds and one genes selected by TD based unsupervised FE were uploaded to Enrichr [20] for enrichment analysis. Full list of enrichment analysis as well as list of 401 genes are accessible at <https://amp.pharm.mssm.edu/Enrichr3/enrich?dataset=5bbbe5602715daf9787895cd16829707>

List of 401 genes and three enrichment analyses used in this study, "LINCS L1000 Chem Pert up", "DrugMatrix" and "Drug Perturbations from GEO up" are also available as supplementary material.

Ranks are based upon adjusted P -values (not those provided by Enrichr).

3 Results

As a unsupervised technique applied to scRNA-seq data set, we employ tensor decomposition [21] that was sometimes applied to gene expression analysis [22].

3.1 Synthetic study of TDs

Before performing TD based unsupervised FE, we perform some synthetic study for some TDs.

We prepared two synthetic data sets, $x_{ijk} \in \mathbb{R}^{N \times N \times N}$ defined as

$$x_{ijk} = v_i v_j v_k + v'_i v'_j v'_k \quad (3)$$

where $v'_i = v_{i+1}$ for $i \leq N - 1$ and $v'_N = v_1$.

For data set 1 (Fig. 1(A) and (B)),

$$v_i = \begin{cases} 0 & 1 \leq i \leq \frac{N}{2} \\ 1 & \frac{N}{2} < i \leq N \end{cases} \quad (4)$$

and for data set 2 (Fig. 1(C) and (D)).

$$v_i = i \quad (5)$$

We apply HOSVD, CP decomposition and CMTF [23] to these two synthetic data set with $N = 10$. At first, we applied HOSVD to data set 1 and 2 as

$$x_{ijk} = \sum_{\ell_1=1}^N \sum_{\ell_2=1}^N \sum_{\ell_3=1}^N G(\ell_1, \ell_2, \ell_3) u_{\ell_1 i}^{(i)} u_{\ell_2 j}^{(j)} u_{\ell_3 k}^{(k)} \quad (6)$$

where $G(\ell_1, \ell_2, \ell_3), u_{\ell_1 i}^{(i)}, u_{\ell_2 j}^{(j)}, u_{\ell_3 k}^{(k)} \in \mathbb{R}^{N \times N \times N}$. Then we noticed that only four G s with $(\ell_1, \ell_2, \ell_3) = (1, 1, 1), (1, 2, 2), (2, 1, 2), (2, 2, 1)$ have non zero values for both data set 1 and 2. Figs. 2 and 3 show $u_{\ell_1 i}^{(i)}, u_{\ell_2 j}^{(j)}, u_{\ell_3 k}^{(k)}$ and

$$\sum_{(\ell_1, \ell_2, \ell_3) \in \{(1,1,1), (1,2,2), (2,1,2), (2,2,1)\}} G(\ell_1, \ell_2, \ell_3) u_{\ell_1 i}^{(i)} u_{\ell_2 j}^{(j)} u_{\ell_3 k}^{(k)} \quad (7)$$

It is obvious that HOSVD successfully performs TD (Figs. 2(C) and 3(C)) although obtained singular value vectors (Figs. 2(A) and (B) and 3(A) and (B)) are not equivalent to Fig. 1 because HOSVD assumes the orthogonality between singular value vectors. The first singular value vectors, $u_{1j}^{(j)}, u_{1i}^{(i)}, u_{1k}^{(k)}$ (Figs. 2(A) and 3(A)), clearly represent somewhat means of $\mathbf{v}$ (Figs. 1(A) and 1(C)) and $\mathbf{v}'$ (Figs. 1(B) and 1(D)) while the second singular value vectors, $u_{2j}^{(j)}, u_{2i}^{(i)}, u_{2k}^{(k)}$ (Figs. 2(B) and 3(B)), clearly represent difference of them.

Next we applied CP decomposition to data set 1 and 2: eqs. (4) and (5) (Fig. 1). It is obvious that CP decomposition (Fig. 4) applied to data set 1 successfully reproduced (Fig. 4(A) and (B)) eq. (3) with eq. (4) (Fig. 1(A) and (B)). On the other hand, CP decomposition (Fig. 5) applied to data set 2 could not, but required up to the third singular value vectors (Fig. 5(A), (B) and (C)). Since CP decomposition depends upon initial values, although we tried multiple initial values, as far as we tried, we could not find the initial values by which CP decomposition can reproduce eq. (3) using eq. (5) (Fig. 1(C) and (D)). In contrast to HOSVD that clearly decomposed $\mathbf{v}$ and $\mathbf{v}'$ into their mean and difference, it is unclear what Fig. 5 represents anymore. Thus, it is obvious whether CP decomposition can perform better than HOSVD is highly dependent upon the data set we analyze. In this sense, HOSVD is less affected by the type of data set analyzed.

Finally, we applied CMTF to data sets 1 and 2 (Fig. 1). In order that, we need to specify loss function, f , to be minimized;

$$f(U^{(i)}, U^{(j)}, U^{(k)}, \mathbf{a}^{(i)}, \mathbf{a}^{(j)}, \mathbf{a}^{(k)}) = \sum_{ijk} \left| x_{ijk} - \sum_{\ell=1}^R u_{\ell i}^{(i)} u_{\ell j}^{(j)} u_{\ell k}^{(k)} \right|^2$$

$$\begin{aligned}
 & + \sum_i \left| v_i - \sum_{\ell=1}^R a_{\ell}^{(i)} u_{\ell i}^{(i)} \right|^2 \\
 & + \sum_j \left| v_j - \sum_{\ell=1}^R a_{\ell}^{(j)} u_{\ell j}^{(j)} \right|^2 \\
 & + \sum_k \left| v_k - \sum_{\ell=1}^R a_{\ell}^{(k)} u_{\ell k}^{(k)} \right|^2
 \end{aligned} \tag{8}$$

where $U^{(i)}, U^{(j)}, U^{(k)} \in \mathbb{R}^{N \times R}$ are defined as

$$U^{(i)} = \begin{pmatrix} \mathbf{u}_1^{(i)} & \cdots & \mathbf{u}_R^{(i)} \end{pmatrix} \tag{9}$$

$$U^{(j)} = \begin{pmatrix} \mathbf{u}_1^{(j)} & \cdots & \mathbf{u}_R^{(j)} \end{pmatrix} \tag{10}$$

$$U^{(k)} = \begin{pmatrix} \mathbf{u}_1^{(k)} & \cdots & \mathbf{u}_R^{(k)} \end{pmatrix} \tag{11}$$

with $\mathbf{u}_{\ell}^{(i)}, \mathbf{u}_{\ell}^{(j)}, \mathbf{u}_{\ell}^{(k)} \in \mathbb{R}^N$ defined as

$$\mathbf{u}_{\ell}^{(i)} = \begin{pmatrix} u_{\ell 1}^{(i)} \\ \vdots \\ u_{\ell N}^{(i)} \end{pmatrix} \tag{12}$$

$$\mathbf{u}_{\ell}^{(j)} = \begin{pmatrix} u_{\ell 1}^{(j)} \\ \vdots \\ u_{\ell N}^{(j)} \end{pmatrix} \tag{13}$$

$$\mathbf{u}_{\ell}^{(k)} = \begin{pmatrix} u_{\ell 1}^{(k)} \\ \vdots \\ u_{\ell N}^{(k)} \end{pmatrix} \tag{14}$$

With coefficient vectors, $\mathbf{a}^{(i)}, \mathbf{a}^{(j)}, \mathbf{a}^{(k)} \in \mathbb{R}^R$, $\mathbf{v}$ is required to be expressed by the linear transformation of $U^{(i)}, U^{(j)}, U^{(k)}$.

After trying to apply CMTF with $R = 2$ (because we know $R = 2$ is enough because of eq. (3)) to data sets 1 and 2, we realized that it is rare that CMTF converges to global minimum when starting from initial values, $U^{(i)}, U^{(j)}, U^{(k)}, \mathbf{a}^{(i)}, \mathbf{a}^{(j)}, \mathbf{a}^{(k)}$, drawn from $\mathcal{N}(0, 1)$ where $\mathcal{N}(\mu, \sigma)$ is normal distribution having mean of μ and standard deviation of σ . After trying several tens of ninital values, we got the results shown in Figs. 6 and 7. It is obvious that CMTF performed quite well as far as it converges. $\mathbf{u}_1^{(i)}, \mathbf{u}_1^{(j)}, \mathbf{u}_1^{(k)}$, (Figs. 6(A) and 7(A)) correspond to $\mathbf{v}$ (Fig. 1(A) and (C)) while $\mathbf{u}_2^{(i)}, \mathbf{u}_2^{(j)}, \mathbf{u}_2^{(k)}$ (Figs. 6(B) and 7(B)), correspond to $\mathbf{v}'$ (Fig. 1(B) and (D)) as expected. On the other hand, it is problematic that CMTF rarely converges to global minimum. In order to improve this points, we replaced ALS employed in CMTF with BFGS.

Now CMTF came to converge to global minimum (Figs. 8 and 9) with starting any initial values drawn from $\mathcal{N}(0, 1)$ as long as we tried. Thus, we decided to apply CMTF with replacing ALS with BFGS.

Although CMTF looks the best method to apply, CMTF has one problem: cpu time required to perform CMTF. Table 1 shows the list of cpu time required when various methods are applied to data set 1 and 2. It is obvious that HOSVD is the fastest since it does not require any iterations. CP decomposition is a bit slower than HOSVD, since it requires ALS to converge. CMTF is much more slower no matter which methods, ALS or BFGS, are employed for the minimization. As far as we deal with small data set, this difference is not critical. Nevertheless, when we have to deal with massive data set, this difference is critical. Although CMTF is slower than HOSVD by only several hundreds times, this difference is generally enhanced when the data set becomes larger. Since cpu time required for HOSVD also increases as data set grows, it might be unrealistic to perform CMTF for much larger data set.

Before applying TDs to real data set, we summarize the results here.

- HOSVD is the fastest and its outcome is not affected by the type of data set much. Nevertheless, because of requirement of orthogonality, it has less ability to derive the structure of original data set, eq. (3), if the vectors used to generate tensor are not orthogonal to each other.
- CP decomposition is the second fastest method and can reproduce the structure of original data set, eq. (3) (Fig. 4). Nonetheless, CP decomposition might fail dependent upon data set (Fig. 5).
- The original CMTF can successfully reproduce the data structure, eq. (3). On the other hand, it is the slowest method and requires to search initial values that converges to global minimum.
- With replacing ALS with BFGS, CMTF comes to converge to global minimum independent of initial values. In spite of the acceleration with this replacement, CMTF is still much slower than HOSVD as well as CP decomposition.

Based upon the observation in the above, since data set we have to analyze is massive, considering primarily the cpu time required, we decided to employ HOSVD first. Then we will try other methods only when HOSVD fails to get reasonable results.

In order to apply the methods to more realistic cases, we added noise to x_{ijk} . According to the results in the Supplementary file, the summary is as follows:

- HOSVD is least affected by adding noise (Figs. S1 and S2). This is because of the following reason. HOSVD generated two $\mathbf{u}_\ell$ s (Fig. 2(A) and (B), 3(A) and (B)), which correspond to those with larger and smaller amplitudes, respectively, because of the requirement of orthogonality. Then $\mathbf{u}_\ell$ s with larger amplitude remained unchanged (Figs. S1(A) and S2(A)). As a result, correspondence between x_{ijk} and the reconstruction (Figs. S1(C) and S2(C)) remained relatively accurate.

- 227 • For CP decomposition, adding noise destroyed the tiny difference among
228 $\mathbf{u}_\ell$ s (Fig. 4 (A) and (B), Fig. 5 (A), (B) and (C)). Then the CP decompo-
229 sition could detect only one valid $\mathbf{u}_\ell$ (Figs. S3(A) and S4(B)). As a result,
230 the obtained $\mathbf{u}_\ell$ do not look better than those obtained by HOSVD (Figs.
231 S1(A) and S2(A)). Then advantages of CP decomposition over HOSVD,
232 which exist when noise free data set is considered, were lost.
 - 233 • Original CMTF failed to converge, since adding noise disrupted computa-
234 tion of gradient that is required to update the $\mathbf{u}_\ell$ by ALS.
 - 235 • Although CMTF with replacing ALS with BFGS still converged (Figs. S5
236 and S6), it was impossible to see which $\mathbf{u}_\ell$ converged correctly, because
237 the converged solution has residuals due to adding noises. As a result, the
238 converged $\mathbf{u}_\ell$ (Figs. S5(A) and S6(B)) do not look better than those for
239 HOSVD (Figs. S1(A) and S2(A)). The correspondence between x_{ijk} and
240 the reconstruction (Figs. S5(D) and S6(D)) even became worst among
241 methods tested. The advantages over HOSVD, which exist when noise
242 free data set is considered, were lost as for CP decomposition.
- 243 In conclusion, adding noise, which is supposed to be closer to a realistic situation,
244 added more advantages to HOSVD than other methods.

245 3.2 Application of HOSVD to real data set

246 Among numerous neurodegenerative diseases, we focus on Alzheimer’s disease
247 (AD) in this study, because it is the diseases for which the most number of drugs
248 were tried to develop. For example, among 322 drugs that target neurodegen-
249 erative diseases, as many as 92 drugs targeted AD [24]. The therapy targets
250 of AD are wide ranged; especially, Amyloid protein was most frequent target
251 (12 among 92 drugs target amyloid), because accumulation of amyloid has ever
252 been believed to be a primary cause of AD.

253 For this purpose, we selected one specific scRNA-seq data set, GSE127891,
254 by which we can demonstrate the effectiveness of our proposed method. When
255 selecting genes using TD based unsupervised FE, we first need to specify what
256 kind of properties of gene expression we consider. In this study, we require the
257 followings.

- 258 1. Gene expression should be independent of cells within the same 96 wells
259 plate.
- 260 2. Gene expression should be independent of genotype.
- 261 3. Gene expression should be independent of tissues.
- 262 4. Gene expression should have monotonic dependence upon age.
- 263 5. Gene expression should be independent of sex.
- 264 6. Gene expression should be independent of each of four 96 wells plates
265 under the same conditions.

In other words, we try to select genes with the most robust monotonic age dependence as much as possible. The reason of this motivation is as follows. In the paper where data set analyzed here was investigated originally, Frigerio et al. [25] found that age is the primary factor of the microglia response to accumulation of A β plaques. We found that singular value vectors with $\ell_1 = \ell_2 = \ell_3 = \ell_5 = \ell_6 = 1$ represent independence of cells, genotypes, tissues, sex and plates (Figure 10 (A), (B), (C), (E), (F)). On the other hand, u_{2j_4} represents monotonic dependence upon ages, $1 \leq j_4 \leq 4$ (Figure 10 (D)).

Next, we need to find the $G(1, 1, 1, 2, 1, 1, \ell_7)$ with the largest absolute value in order to identify singular value vector, $u_{\ell_7 i}$, attributed to genes. Then we found that $G(1, 1, 1, 2, 1, 1, 2)$ has the largest absolute value. Therefore, we decided to use u_{2i} for attributing P -values to genes as shown in eq. (2). Finally, 401 genes are identified as being associated with adjusted P -values less than 0.01 (The list of genes is available as supplementary material).

These 401 genes are uploaded to Enrichr to identify the compounds, with which genes expressing differential expression of cell lines treated are maximally overlapped with these 401 genes. As for “LINCS L1000 Chem Pert up” category (Table 2, full list is available as supplementary material), the top ranked compound is alvocidib, which was previously tested for AD [26]; there are also 65 experiments (see supplementary material) of cell lines treated with alvocidib and associated with adjusted P -value less than 0.05. The second top ranked compound is AZD-8055, which was also previously tested for AD [27]; there are also 6 experiments (see supplementary material) of cell lines treated with AZD-8055 and associated with adjusted P -value less than 0.05.

One might wonder if this is an accidental agreement which is specific to LINCS data set. In order to confirm that it is not an accidental agreement, we also see DrugMatrix category (Table 3, full list is available as supplementary material). The top, fifth and tenth ranked compound is cyclosporin-A, which was also previously tested for AD [28]; there are also 57 experiments (see supplementary material) of cell lines treated with cyclosporin-A and associated with adjusted P -value less than 0.05. Finally, we tested “Drug Perturbations from GEO up” category in Enrichr (Table 4, full list is available as supplementary material). The top ranked compounds is imatinib, which was also previously tested for AD [29]; there are also 18 experiments (see supplementary material) of cell lines treated with imatinib and associated with adjusted P -value less than 0.05.

In order to check if the results are relatively independent of threshold adjusted P -value, we also checked two additional threshold P -values, 0.005 and 0.05 (See Table 5). Although the threshold adjusted P -values less than 0.01 is the best, other two choices achieve almost similar performance. Thus, the performance achieved seems to be robust.

Although these findings suggest that our strategy is effective to find compounds that can be used for AD treatment, one might think that these findings are still weak. Since these 401 genes are simply genes whose expression is altered because of Amyloid accumulation, they themselves are unlikely to be disease causing genes. Thus we consider regulation factors that affect expression of these

genes. At first, we consider transcription factor (TF). With checking “ENCODE and ChEA Consensus TFs from ChIP-X” category in Enrichr, we found that the target genes of TFs, MYC, NELFE, TAF7, KAT2A, SPI1, RELA, TAF1 and PML are top ranked ten TFs associated with adjusted P -values less than 1×10^{-7} (They are less than ten, because some are ranked in multiple times within top 10). Among them, MYC [30], KAT2A [31], SPI1 [32], RELA [33], TAF1 [34], and PML [35] were reported to be related to AD. These TFs were also identified within top ranked 10 TFs, with other two additional threshold P -values, less than 0.005 and 0.05, with similar associated adjusted P -values; no additional TFs were ranked within top 10.

Next we consider microRNA (miRNA) as regulatory factors towards identified 401 genes. With checking “miRTarBase 2017” category in Enrichr, we found that target genes of miRNAs, hsa-miR-320a, hsa-miR-1260b, hsa-miR-652-3p, hsa-miR-744-5p, hsa-miR-16-5p, hsa-miR-100-5p, hsa-miR-615-3p, hsa-miR-484, hsa-miR-296-3p, and hsa-miR-423-5p are top ranked ten miRNAs associated with adjusted P -values less than 1×10^{-3} . Among them, miR-320a [36], miR-652 [37], miR-744 [38], miR-16 [39], miR-100 [40], miR-615 [41], miR-484 [42], miR-296 [43], and miR-423 [36] were reported to be related to AD. As for additional two threshold adjusted P -values, all are ranked within top 10 for adjusted P -values less than 0.05 while eight out of ten excluding miR-615-3p and miR-296-3p are ranked within top 10. Thus, it also shows a robust result.

These finding can add more confidence that identified 401 genes are likely related to AD. Expression of these 401 genes might be altered because they are simply downstream genes caused by AD, it is unlikely to find more direct evidence that these genes really contribute to AD directly. For our purpose, screening drugs with gene expression, 401 genes are enough to be downstream genes caused by AD. Thus, we do not investigate biological background of these 401 genes further.

Thus, it might be worthwhile investigating lower ranked compounds in Tables 2, 3 and 4 as candidate compounds for AD, even if they were not known drugs for AD.

4 Discussion

First of all, since these cell lines in Table 2 are originated in human, our strategy can provide us the opportunity to check if proposed candidate drugs screened with model animals are also effective in human.

It is also remarkable that we do not need gene expression of all genes, but only a subset of genes (please remember that LINCS project measures only gene expression of less than one thousand genes) in order to predict candidate drugs with high accuracy. This might reduce the amount of money to screen numerous number of compounds.

Our method is also applicable to scRNA-seq in order to screen drug compounds candidate from scRNA-seq. To our knowledge, there are very limited number of studies that relate scRNA-seq to drug design [44,45], since scRNA-seq

usually lacks cell labeling which is useful to screen differentially expressed genes. In this study, we simply make use of ages, which is not always directly related to diseases. In spite of that, drug we listed was correct, i.e., they are known drugs to some extent. Therefore, our strategy is also useful to add an alternative one along this direction, i.e., making use of scRNA-seq for drug design.

Thus, our strategy, TD based unsupervised FE, might be promising methodology to screen drug candidate compounds.

One might wonder why we have specifically used HOSVD algorithm although there are many other ways by which we can apply TD to data set. There are multiple reasons why we did not employ other TD based approaches. First of all, we would like to compare HOSVD with other simple (unsupervised) TDs, CP decomposition, HOOI for Tucker decomposition and tensor train decomposition. CP decomposition is the much more popular methods because it can relate singular value vectors one to one. In HOSVD algorithm, we need to investigate core tensor, G , for relating singular value vectors attributed to genes and those attributed to individual cells. In CP decomposition, since TD is composed of outer product of individual singular value vectors, it is clear which singular value vectors attributed to genes are associated with selected singular value vectors attributed to cells. Nevertheless, CP decomposition has two disadvantages: massive computational time and the lack of guarantee that converges to unique solutions. Since CP decomposition employed alternative least square (ALS), it needs to initial values of singular value vectors, which often converges to distinct final singular value vectors. This results in distinct set of genes selected, since we make use of singular value vectors attributed to genes in order to select genes. It definitely prevents us from interpreting biological meanings that should be independent of numerical initial values. The employment of ALS also results in the lack of estimated computational time, since it is iterative procedure. Especially when we need to deal with massive data set that require huge cpu time in each iteration, it is not a good strategy to employ the method that requires iterative processes that we cannot estimate the cpu time require by it in advance. On the other hand, HOSVD is essentially SVD of unfolded tensor, thus it does not require any iterative computation; it is guaranteed to converge within polynomial time. Since we could get reasonable results using HOSVD, we have no motivation to employ the method that requires iteration like CP decomposition. As for HOOI, since it also employed ALS, it is not recommended to employ for the massive data set that we analyzed in this study. Especially, since it is very usual that HOOI employs the results of HOSVD as initial (starting) values for the iteration, there are no reasons to apply HOOI to the results of HOSVD that is good enough in this study. Finally, as for tensor train decomposition, it does lack the weight factor that relates between singular value vectors attributed to gene and cells. Since we definitely need to relate them for our purpose, tensor train decomposition is not a suitable method, either. All of these point about the comparisons between HOSVD and other TDs from the point of views of feature selection was discussed in more details in the book [9] to be published soon.

After that, we would like to discuss why we do not employ more advanced

supervised methods. In the above analysis, we made use of labeling information, e.g., sex, genotypes, and time points, only after TD was applied to data set. On the other hand, there are multiple methods that can make use of labeling information with applying TD. For example, coupled matrix and tensor factorization (CMTF) [23] is a straight extension of unsupervised TD to supervised one. CMTF requires that linear combination of singular value vectors must be coincident with given labeling attributed to samples (in this study, cells). Although it is generally expected that CMTF can derive singular value vectors that are more associated with labeling than fully unsupervised TDs do, only one obstacle to perform CMTF is cpu time. Since CMTF requires iterative optimization to fulfill the requirements, i.e., linear combination of singular value vectors must be coincident with given labeling attributed to sample, CMTF requires more computational time than unsupervised TD including HOSVD do. Practically, CMTF requires as many as hundreds iterations, each of which requires cpu time as much as HOSVD requires. This means, CMTF takes as many as hundreds times longer than HOSVD. In this case, since data set is so massive, single HOSVD requires several hours run on computer, Although we tried to implement CMTF fitted to our model and to execute it, it does not converge within a day. Since our TD based unsupervised FE has already achieved reasonable results we concluded that performing more advanced supervised methods that usually require more cputime is not effective and did not employ any supervised method including CMTF.

5 Conclusion and Future Work

In this paper, we applied TD based unsupervised FE to scRNA-seq taken from mouse brain with A β accumulation. We have compared selected 401 genes with differentially expressed genes in cell lines and model animals treated with various compounds. As a result, as for three independent data sets, LINCS, DrugMatrix and GEO, top ranked compounds are reported to be tested as AD treatment. This suggests the effectiveness of our strategy and lower ranked compounds should be tested as promising drug compounds candidates. To our knowledge, this is the first successful one that can be applied to scRNA-seq in order to identify drug compounds candidate.

For future work, we aim to (1) utilize the tensor decomposition technique in the transfer learning setting to identify effective drugs between target and related tasks in various problems in the clinical informatics domain, among other uses; (2) add other data source of different diseases (e.g., Parkinson's disease) for treatment validation; and (3) apply the tensor decomposition technique in more fields such as social networks to verify its effectiveness in applications such as recommender systems.

440 6 Acknowledgement

441 This project was funded by the Deanship of Scientific Research (DSR) at King
 442 Abdulaziz University, Jeddah, under grant no. KEP-8-611-38. The authors,
 443 therefore, acknowledge with thanks DSR for technical and financial support.
 444 This paper was also funded by KAKENHI 19H05270 and 17K00417.

References

- [1] Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. *Neuropharmacology*. 2017;120:11 – 19. Beyond Small Molecules for Neurological Disorders.
- [2] Ransohoff RM. All (animal) models (of neurodegeneration) are wrong. Are they also useful? *Journal of Experimental Medicine*. 2018;215(12):2955–2958.
- [3] Gordon J, Amini S, White MK. In: Amini S, White MK, editors. *General Overview of Neuronal Cell Culture*. Totowa, NJ: Humana Press; 2013. p. 1–8.
- [4] Habib R, Noureen N, Nadeem N. Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways. *Current Genomics*. 2018;19(4):300–312.
- [5] Avsec Ž, Kreuzhuber R, Israeli J, Xu N, Cheng J, Shrikumar A, et al. The Kipoi repository accelerates community exchange and reuse of predictive models for genomics. *Nature biotechnology*. 2019;p. 1.
- [6] Badrinarayanan V, Kendall A, Cipolla R. Segnet: A deep convolutional encoder-decoder architecture for image segmentation. *IEEE transactions on pattern analysis and machine intelligence*. 2017;39(12):2481–2495.
- [7] Mehdipour Ghazi M, Kemal Ekenel H. A comprehensive analysis of deep learning based representation for face recognition. In: *Proceedings of the IEEE conference on computer vision and pattern recognition workshops*; 2016. p. 34–41.
- [8] Taguchi Y. Multiomics Data Analysis Using Tensor Decomposition Based Unsupervised Feature Extraction. In: *Intelligent Computing Theories and Application*. Springer International Publishing; 2019. p. 565–574. Available from: https://doi.org/10.1007/978-3-030-26763-6_54.
- [9] Taguchi YH. Unsupervised Feature Extraction Applied to Bioinformatics: A PCA Based and TD Based Approach. *Unsupervised and Semi-Supervised Learning*. Springer International Publishing; 2019. In press.

- [10] Taguchi Yh. Drug candidate identification based on gene expression of treated cells using tensor decomposition-based unsupervised feature extraction for large-scale data. *BMC Bioinformatics*. 2019 Feb;19(13):388.
- [11] Taguchi YH, Ng KL. Tensor Decomposition-Based Unsupervised Feature Extraction for Integrated Analysis of TCGA Data on MicroRNA Expression and Promoter Methylation of Genes in Ovarian Cancer. In: 2018 IEEE 18th International Conference on Bioinformatics and Bioengineering (BIBE); 2018. p. 195–200.
- [12] Taguchi YH. Tensor Decomposition-Based Unsupervised Feature Extraction Can Identify the Universal Nature of Sequence-Nonspecific Off-Target Regulation of mRNA Mediated by MicroRNA Transfection. *Cells*. 2018;7(6):54.
- [13] Taguchi YH. Tensor decomposition/principal component analysis based unsupervised feature extraction applied to brain gene expression and methylation profiles of social insects with multiple castes. *BMC Bioinformatics*. 2018;19(Suppl 4):99.
- [14] Taguchi YH. One-class Differential Expression Analysis using Tensor Decomposition-based Unsupervised Feature Extraction Applied to Integrated Analysis of Multiple Omics Data from 26 Lung Adenocarcinoma Cell Lines. In: 2017 IEEE 17th International Conference on Bioinformatics and Bioengineering (BIBE); 2017. p. 131–138.
- [15] Taguchi YH. Tensor decomposition-based unsupervised feature extraction applied to matrix products for multi-view data processing. *PLoS ONE*. 2017;12(8):e0183933.
- [16] Taguchi YH. Identification of candidate drugs using tensor-decomposition-based unsupervised feature extraction in integrated analysis of gene expression between diseases and DrugMatrix datasets. *Sci Rep*. 2017;7(1):13733.
- [17] Taguchi YH. Tensor decomposition-based unsupervised feature extraction identifies candidate genes that induce post-traumatic stress disorder-mediated heart diseases. *BMC Med Genomics*. 2017;10(Suppl 4):67.
- [18] Taguchi YH. Identification of Candidate Drugs for Heart Failure Using Tensor Decomposition-Based Unsupervised Feature Extraction Applied to Integrated Analysis of Gene Expression Between Heart Failure and Drug-Matrix Datasets. In: *Intelligent Computing Theories and Application*. Springer International Publishing; 2017. p. 517–528.
- [19] Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995;57(1):289–300.

- [20] Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Research*. 2016 05;44(W1):W90–W97.
- [21] Kolda TG, Bader BW. Tensor decompositions and applications. *SIAM review*. 2009;51(3):455–500.
- [22] Hore V, Viñuela A, Buil A, Knight J, McCarthy MI, Small K, et al. Tensor decomposition for multiple-tissue gene expression experiments. *Nature genetics*. 2016;48(9):1094.
- [23] Acar E, Rasmussen MA, Savorani F, Næs T, Bro R. Understanding data fusion within the framework of coupled matrix and tensor factorizations. *Chemometrics and Intelligent Laboratory Systems*. 2013;129:53 – 63. Multiway and Multiset Methods. Available from: <http://www.sciencedirect.com/science/article/pii/S0169743913001226>.
- [24] Fischer F, Matthiesson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. *Neurodegenerative Diseases*. 2004;1(1):50–70. Available from: <https://doi.org/10.1159/2F000077879>.
- [25] Frigerio CS, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, et al. The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to A β Plaques. *Cell Reports*. 2019;27(4):1293 – 1306.e6.
- [26] Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W, et al. The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid β_{1-42} oligomers in mice. *Pharmacological Research*. 2016;106:10 – 20.
- [27] Hein LK, Apaja PM, Hattersley K, Grose RH, Xie J, Proud CG, et al. A novel fluorescent probe reveals starvation controls the commitment of amyloid precursor protein to the lysosome. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*. 2017;1864(10):1554 – 1565.
- [28] Heuvel CVD, Donkin JJ, Finnie JW, Blumbergs PC, Kuchel T, Koszyca B, et al. Downregulation of Amyloid Precursor Protein (APP) Expression following Post-Traumatic Cyclosporin-A Administration. *Journal of Neurotrauma*. 2004;21(11):1562–1572. PMID: 15684649.
- [29] Eisele YS, Baumann M, Klebl B, Nordhammer C, Jucker M, Kilger E. Gleevec Increases Levels of the Amyloid Precursor Protein Intracellular Domain and of the Amyloid-egrading Enzyme Neprilysin. *Molecular Biology of the Cell*. 2007;18(9):3591–3600. PMID: 17626163.
- [30] Ferrer I, Blanco R. N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease. *Molecular Brain Research*. 2000;77(2):270 – 276. Available from: <http://www.sciencedirect.com/science/article/pii/S0169328X00000620>.

- [31] Kerimoglu C, Sakib MS, Jain G, Benito E, Burkhardt S, Capece V, et al. KMT2A and KMT2B Mediate Memory Function by Affecting Distinct Genomic Regions. *Cell Reports*. 2017;20(3):538 – 548. Available from: <http://www.sciencedirect.com/science/article/pii/S2211124717309038>.
- [32] Huang KL, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. *Nat Neurosci*. 2017 Aug;20(8):1052–1061.
- [33] Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, et al. Increased NF- κ B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. *International Journal of Neuropsychopharmacology*. 2012 02;15(1):77–90. Available from: <https://doi.org/10.1017/S1461145711000149>.
- [34] Muller U, Herzfeld T, Nolte D. The TAF1/DYT3 multiple transcript system in X-linked dystonia-parkinsonism. *Am J Hum Genet*. 2007 Aug;81(2):415–417.
- [35] Kelleher MB, Galutira D, Duggan TD, Nuovo GJ. Progressive multifocal leukoencephalopathy in a patient with Alzheimer’s disease. *Diagn Mol Pathol*. 1994 Jun;3(2):105–113.
- [36] Nagaraj S, Laskowska-Kaszub K, D?bski KJ, Wojsiat J, D?browski M, Gabryelewicz T, et al. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects. *Oncotarget*. 2017 Mar;8(10):16122–16143.
- [37] Wang LL, Min L, Guo QD, Zhang JX, Jiang HL, Shao S, et al. Profiling microRNA from Brain by Microarray in a Transgenic Mouse Model of Alzheimer’s Disease. *Biomed Res Int*. 2017;2017:8030369.
- [38] Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, et al. Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer’s and Parkinson’s Diseases Correlate with Disease Status and Features of Pathology. *PLOS ONE*. 2014 05;9(5):1–20. Available from: <https://doi.org/10.1371/journal.pone.0094839>.
- [39] Zhang B, Chen CF, Wang AH, Lin QF. MiR-16 regulates cell death in Alzheimer’s disease by targeting amyloid precursor protein. *Eur Rev Med Pharmacol Sci*. 2015 Nov;19(21):4020–4027.
- [40] Hebert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer’s disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. *J Alzheimers Dis*. 2013;35(2):335–348.

- [41] Liu QY, Chang MN, Lei JX, Koukiekolo R, Smith B, Zhang D, et al. Identification of microRNAs involved in Alzheimer’s progression using a rabbit model of the disease. *Am J Neurodegener Dis.* 2014;3(1):33–44.
- [42] Rani A, O’Shea A, Ianov L, Cohen RA, Woods AJ, Foster TC. miRNA in Circulating Microvesicles as Biomarkers for Age-Related Cognitive Decline. *Frontiers in Aging Neuroscience.* 2017;9:323. Available from: <https://www.frontiersin.org/article/10.3389/fnagi.2017.00323>.
- [43] Xie B, Zhou H, Zhang R, Song M, Yu L, Wang L, et al. Serum miR-206 and miR-132 as Potential Circulating Biomarkers for Mild Cognitive Impairment. *J Alzheimers Dis.* 2015;45(3):721–731.
- [44] Litzenburger UM, Buenrostro JD, Wu B, Shen Y, Sheffield NC, Kathiria A, et al. Single-cell epigenomic variability reveals functional cancer heterogeneity. *Genome Biology.* 2017 Jan;18(1):15.
- [45] Yuan D, Tao Y, Chen G, Shi T. Systematic expression analysis of ligand-receptor pairs reveals important cell-to-cell interactions inside glioma. *Cell Communication and Signaling.* 2019 May;17(1):48.

	HOSVD	CP	CMTF	
			ALS	BFGS
data set 1	22	334	5760	2002
data set 2	9	123	5787	2991

Table 1: Cpu time (msec) required to perform various methods.

Table 2: Top ranked 10 compounds listed in “LINCS L1000 Chem Pert up” category in Enrichr. Overlap is that between selected 401 genes and genes selected in individual experiments.

Term	Overlap	P-value	Adjusted P-value
LJP006.HCC515.24H-alvocidib-10	28/221	7.99×10^{-15}	2.21×10^{-10}
LJP006.HCC515.24H-AZD-8055-10	24/188	5.87×10^{-13}	8.13×10^{-9}
LJP009.PC3.24H-CGP-60474-3.33	25/217	1.99×10^{-12}	1.14×10^{-8}
LJP005.MDAMB231.24H-AS-601245-10	20/132	2.05×10^{-12}	1.14×10^{-8}
LJP009.PC3.24H-saracatinib-10	24/196	1.47×10^{-12}	1.14×10^{-8}
LJP006.HCC515.24H-CGP-60474-0.37	24/225	2.89×10^{-11}	1.14×10^{-7}
LJP009.PC3.24H-PF-3758309-10	23/212	5.33×10^{-11}	1.84×10^{-7}
LJP005.HCC515.24H-WZ-3105-3.33	20/144	1.07×10^{-11}	4.95×10^{-8}
LJP006.HEPG2.24H-AZD-5438-10	21/182	1.17×10^{-10}	3.24×10^{-7}
LJP006.HCC515.24H-A443654-10	22/203	1.44×10^{-10}	3.62×10^{-7}

Figure 1: Data set 1, eq. (4), (A) v_i and (B) v'_i and data set 2, eq. (5), (C) v_i and (D) v'_i .

Figure 2: The results obtained by HOSVD applied to data set 1: eq. (4). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Scatter plot between x_{ijk} (horizontal axis) and eq. (7) (vertical axis).

Figure 3: The results obtained by HOSVD applied to data set 2: eq. (5). Other notations are the same as Fig. 2.

Figure 4: The results obtained by CP decomposition applied to data set 1: eq. (4). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Scatter plot between x_{ijk} (horizontal axis) and those reproduced by CP decomposition using singular value vectors shown in (A) and (B) (vertical axis).

Figure 5: The results obtained by CP decomposition applied to data set 2: eq. (5). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Open black circles: $u_{3i}^{(i)}$, open red triangles: $u_{3j}^{(j)}$, blue pluses: $u_{3k}^{(k)}$. (D) Scatter plot between x_{ijk} (horizontal axis) and those reproduced by CP decomposition using singular value vectors shown in (A), (B) and (C) (vertical axis).

Figure 6: The results obtained by CMTF applied to data set 1: eq. (4). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Open black circles: $a_{\ell}^{(i)}$, open red triangles: $a_{\ell}^{(j)}$, blue pluses: $a_{\ell}^{(k)}$. (D) Scatter plot between x_{ijk} (horizontal axis) and those reproduced by CMTF decomposition using singular value vectors shown in (A) and (B) (vertical axis).

Figure 7: The results obtained by CMTF applied to data set 2: eq. (5). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Open black circles: $a_\ell^{(i)}$, open red triangles: $a_\ell^{(j)}$, blue pluses: $a_\ell^{(k)}$. (D) Scatter plot between x_{ijk} (horizontal axis) and those reproduced by CMTF decomposition using singular value vectors shown in (A) and (B) (vertical axis).

Figure 8: The results obtained by CMTF, with replacing ALS with BFGS, applied to data set 1: eq. (4). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Open black circles: $a_{\ell}^{(i)}$, open red triangles: $a_{\ell}^{(j)}$, blue pluses: $a_{\ell}^{(k)}$. (D) Scatter plot between x_{ijk} (horizontal axis) and those reproduced by CMTF using singular value vectors shown in (A) and (B) (vertical axis).

Figure 9: The results obtained by CMTF, with replacing ALS with BFGS, applied to data set 2: eq. (5). (A) Open black circles: $u_{1i}^{(i)}$, open red triangles: $u_{1j}^{(j)}$, blue pluses: $u_{1k}^{(k)}$ (B) Open black circles: $u_{2i}^{(i)}$, open red triangles: $u_{2j}^{(j)}$, blue pluses: $u_{2k}^{(k)}$. (C) Open black circles: $a_{\ell}^{(i)}$, open red triangles: $a_{\ell}^{(j)}$, blue pluses: $a_{\ell}^{(k)}$. (D) Scatter plot between x_{ijk} (horizontal axis) and those reproduced by CMTF using singular value vectors shown in (A) and (B) (vertical axis).

Figure 10: Singular value vectors. (A) u_{1j_1} (B) u_{1j_2} (C) u_{1j_3} (D) u_{2j_4} (E) u_{1j_5} (F) u_{1j_6} .

Table 3: Top ranked 10 compounds listed in “DrugMatrix” category in Enrichr. Overlap is that between selected 401 genes and genes selected in individual experiments.

Term	Overlap	P-value	Adjusted P-value
Cyclosporin_A-350_mg/kg_in_Corn_Oil-Rat-Bone_marrow-5d-up	51/315	2.26×10^{-31}	1.78×10^{-27}
Isoprenaline-4.2_mg/kg_in_Saline-Rat-Heart-5d-up	49/304	4.55×10^{-30}	1.79×10^{-26}
Hydroxyurea-400_mg/kg_in_Saline-Rat-Bone_marrow-5d-up	46/307	7.54×10^{-27}	1.49×10^{-23}
Netilmicin-40_mg/kg_in_Saline-Rat-Kidney-28d-up	45/314	1.90×10^{-25}	1.50×10^{-22}
Cyclosporin_A-350_mg/kg_in_Corn_Oil-Rat-Bone_marrow-3d-up	45/312	1.45×10^{-25}	1.42×10^{-22}
Chlorambucil-0.6_mg/kg_in_Corn_Oil-Rat-Spleen-0.25d-up	47/314	2.13×10^{-27}	5.60×10^{-24}
Tobramycin-40_mg/kg_in_Saline-Rat-Kidney-28d-up	45/311	1.26×10^{-25}	1.42×10^{-22}
Gemcitabine-11_mg/kg_in_Saline-Rat-Bone_marrow-3d-up	47/344	1.27×10^{-25}	1.42×10^{-22}
Terbutaline-130_mg/kg_in_Corn_Oil-Rat-Heart-3d-up	45/321	4.89×10^{-25}	2.41×10^{-22}
Cyclosporin_A-70_mg/kg_in_Corn_Oil-Rat-Bone_marrow-3d-up	45/320	4.28×10^{-25}	2.25×10^{-22}

Table 4: Top ranked 10 compounds listed in “Drug Perturbations from GEO up” category in Enrichr. Overlap is that between selected 401 genes and genes selected in individual experiments.

Term	Overlap	P-value	Adjusted P-value
imatinib DB00619 mouse GSE51698 sample 2522	81/288	2.27×10^{-70}	2.05×10^{-67}
bleomycin DB00290 mouse GSE2640 sample 2851	80/329	6.09×10^{-64}	2.75×10^{-61}
soman 7305 rat GSE13428 sample 2640	86/532	3.87×10^{-53}	3.50×10^{-51}
coenzyme Q10 5281915 mouse GSE15129 sample 3464	76/302	6.84×10^{-62}	2.06×10^{-59}
N-METHYLFORMAMIDE 31254 rat GSE5509 sample 3570	70/283	2.39×10^{-56}	3.60×10^{-54}
Calcitonin 16132288 mouse GSE60761 sample 3446	65/220	8.51×10^{-58}	1.92×10^{-55}
cyclophosphamide 2907 mouse GSE2254 sample 3626	78/413	2.47×10^{-53}	2.48×10^{-51}
Calcitonin 16132288 mouse GSE60761 sample 3447	59/177	5.88×10^{-56}	7.59×10^{-54}
PRISTANE 15979 mouse GSE17297 sample 3229	71/291	1.03×10^{-56}	1.87×10^{-54}
coenzyme Q10 5281915 mouse GSE15129 sample 3456	76/396	1.79×10^{-52}	1.35×10^{-50}

Table 5: Summary of enrichment analysis for three threshold adjusted P-value

threshold adjusted P-value	0.005	0.01	0.005
the number of genes	370	401	498
LINCS_L1000_Chem_Pert_up			
	rank		
alvocidib	2nd	1st	1st
AZD-8055	1st	2nd	3rd
number of experiments associated with adjusted P-values less than 0.05			
alvocidib	38	65	52
AZD-8055	23	6	13
DrugMatrix			
	rank		
cyclosporin-A	2nd,5th,11th	1st,5th,10th	2nd, 5th, 7th
number of experiments associated with adjusted P-values less than 0.05			
cyclosporin-A	28	57	28
Drug_Perturbations_from_GEO_up			
	rank		
imatinib	1st	1st	1st
number of experiments associated with adjusted P-values less than 0.05			
imatinib	18	18	19